How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,552 results for

Ivermectin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis. (PubMed)

Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis. Onchocerciasis, also known as "river blindness," is a parasitic disease that is caused by infection from the filarial nematode (roundworm), Onchocerca volvulus. Nematodes are transmitted from person to person by blackflies of the Simulium genus, which usually breed in fast flowing streams and rivers. The disease is the second leading infectious cause of blindness in endemic areas.Ivermectin (...) (a microfilaricide) is widely distributed to endemic populations for prevention and treatment of onchocerciasis. Doxycycline, an antibiotic, targets Wolbachia organisms that are crucial to the survival of adult onchocerca (macrofilaricide). Combined treatment with both drugs is believed to cause direct microfilarial death by ivermectin and indirect macrofilarial death by doxycycline. Long-term reduction in the numbers of microfilaria in the skin and eyes and in the numbers of adult worms in the body has

Full Text available with Trip Pro

2016 Cochrane

2. Treatment of scabies: 5% permethrin cream or oral ivermectin?

Treatment of scabies: 5% permethrin cream or oral ivermectin? Prescrire IN ENGLISH - Spotlight ''Treatment of scabies. 5% permethrin cream or oral ivermectin?'', 1 June 2019 {1} {1} {1} | | > > > Treatment of scabies. 5% permethrin cream or oral ivermectin? Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the June issue of Prescrire (...) International - Treatment of scabies: 5% permethrin cream or oral ivermectin? FREE DOWNLOAD In patients with scabies, topical application of 5% permethrin cream and oral ivermectin have a similar harm-benefit balance. How do these two treatment options stack up? Full text available for free download. Summary According to a meta-analysis of six randomised trials, including a total of about 600 patients with scabies, 5% permethrin cream seems to be more rapidly effective than oral ivermectin. Two weeks after

2019 Prescrire

3. Ivermectin for Parasitic Skin Infections of Lice: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Ivermectin for Parasitic Skin Infections of Lice: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Ivermectin for Parasitic Skin Infections of Lice: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Ivermectin for Parasitic Skin Infections of Lice: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Ivermectin for Parasitic Skin Infections of Lice: A Review (...) of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 14, 2019 Project Number: RC1115-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of oral versus topical ivermectin for parasitic skin infections of lice? What is the comparative clinical effectiveness of oral ivermectin versus pediculicides for parasitic skin infections of lice? What is the comparative

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Ivermectin for Parasitic Skin Infections (...) of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 16, 2019 Project Number: RC1116-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of oral versus topical ivermectin for parasitic skin infections of scabies? What is the comparative clinical effectiveness of oral ivermectin versus scabicides for parasitic skin infections of scabies

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Ivermectin and permethrin for treating scabies. (PubMed)

Ivermectin and permethrin for treating scabies. Scabies is an intensely itchy parasitic infection of the skin. It occurs worldwide, but is particularly problematic in areas of poor sanitation, overcrowding, and social disruption. In recent years, permethrin and ivermectin have become the most relevant treatment options for scabies.To assess the efficacy and safety of topical permethrin and topical or systemic ivermectin for scabies in people of all ages.We searched the following databases up (...) trials.We included randomized controlled trials that compared permethrin or ivermectin against each other for people with scabies of all ages and either sex.Two review authors independently screened the identified records, extracted data, and assessed the risk of bias for the included trials.The primary outcome was complete clearance of scabies. Secondary outcomes were number of participants re-treated, number of participants with at least one adverse event, and number of participants withdrawn from

2018 Cochrane

6. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. (PubMed)

A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. Randomized controlled studies of combination therapies in rosacea are limited.Evaluate efficacy and safety of combining ivermectin 1% cream (IVM) and doxycycline 40 mg modified-release capsules∗ (DMR) versus IVM and placebo (PBO) for treatment of severe rosacea.This 12-week

Full Text available with Trip Pro

2019 Journal of American Academy of Dermatology

7. Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for treatment of onchocerciasis - a randomized open-label clinical trial. (PubMed)

Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for treatment of onchocerciasis - a randomized open-label clinical trial. Improved treatment for onchocerciasis is needed to accelerate onchocerciasis elimination in Africa. Aiming to better exploit registered drugs, this study was undertaken to determine whether annual or semiannual treatment with ivermectin (IVM; 200µg/kg) plus albendazole (ALB; 800mg single dose) is superior to IVM alone.This trial was performed

2019 Clinical Infectious Diseases

8. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. (PubMed)

Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Strongyloidiasis is a gut infection with Strongyloides stercoralis which is common world wide. Chronic infection usually causes a skin rash, vomiting, diarrhoea or constipation, and respiratory problems, and it can be fatal in people with immune deficiency. It may be treated with ivermectin or albendazole or thiabendazole.To assess the effects of ivermectin versus benzimidazoles (albendazole (...) abstracts.Randomized controlled trials of ivermectin versus albendazole or thiabendazole for treating chronic strongyloides infection.Two review authors independently extracted data and assessed risk of bias in the included trials. We used risk ratios (RRs) with 95% confidence intervals (CIs) and fixed- or random-effects models. We pooled adverse event data if the trials were sufficiently similar in their adverse event definitions.We included seven trials, enrolling 1147 participants, conducted between 1994

Full Text available with Trip Pro

2016 Cochrane

9. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. (PubMed)

Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Ivermectin is widely used in mass drug administrations for controlling neglected parasitic diseases, and can be lethal to malaria vectors that bite treated humans. Therefore, it could be a new tool to reduce plasmodium transmission. We tested the hypothesis that frequently repeated mass administrations of ivermectin to village residents would reduce clinical (...) malaria episodes in children and would be well tolerated with minimal harms.We invited villages (clusters) in Burkina Faso to participate in a single-blind (outcomes assessor), parallel-assignment, two-arm, cluster-randomised trial over the 2015 rainy season. Villages were assigned (1:1) by random draw to either the intervention group or the control group. In both groups, all eligible participants who consented to the treatment and were at least 90 cm in height received single oral doses of ivermectin

2019 Lancet

10. Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil

Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil (...) Ltda, Brazil) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference

2017 Clinical Trials

11. Adherence to ivermectin is more associated with perceptions of community directed treatment with ivermectin organization than with onchocerciasis beliefs (PubMed)

Adherence to ivermectin is more associated with perceptions of community directed treatment with ivermectin organization than with onchocerciasis beliefs The fight against onchocerciasis in Africa has boomed thanks to the Community Directed Treatment with Ivermectin (CDTI) program. However, in Cameroon, after more than 15 years of mass treatment, onchocerciasis prevalence is still above the non-transmission threshold. This study aimed to explore a possible association between people's beliefs (...) /perceptions of onchocerciasis and of CDTI program, and their adherence to ivermectin in three regions of Cameroon.A cross sectional survey was carried out in three health districts with persistent high onchocerciasis prevalence. Participants were randomly selected in 30 clusters per district. Adherence to ivermectin was comparable between Bafang and Bafia (55.0% and 48.8%, respectively, p>0.05) and lower in Yabassi (40.7%). Among all factors related to program perceptions and disease representations

Full Text available with Trip Pro

2017 PLoS neglected tropical diseases

12. Systematic review with meta analysis: Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectively

Systematic review with meta analysis: Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectively Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectively | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our (...) or password? You are here Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectively Article Text Therapeutics/Prevention Systematic review with meta analysis Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectively Dora Buonfrate , Federico Gobbi

2016 Evidence-Based Medicine (Requires free registration)

13. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. (PubMed)

Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. The morbidity and socioeconomic effects of onchocerciasis, a parasitic disease that is primarily endemic in sub-Saharan Africa, have motivated large morbidity and transmission control programmes. Annual community-directed ivermectin treatment has substantially reduced prevalence. Elimination requires (...) by sex and level of infection, to receive a single oral dose of 8 mg moxidectin or 150 μg/kg ivermectin as overencapsulated oral tablets. The primary efficacy outcome was skin microfilariae density 12 months post treatment. We used a mixed-effects model to test the hypothesis that the primary efficacy outcome in the moxidectin group was 50% or less than that in the ivermectin group. The primary efficacy analysis population were all participants who received the study drug and completed 12-month

Full Text available with Trip Pro

2018 Lancet

14. Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System (PubMed)

Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System The mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-endemic.The objective of the current study was to describe the central and peripheral (...) nervous system disorders that occurred after mass administration of ivermectin in Democratic Republic of Congo (DRC).This is a retrospective descriptive study involving a review of data on adverse events related to mass administration of ivermectin. Data on reported serious adverse events following mass administration of ivermectin in the DRC were extracted from the World Health Organization (WHO) Global individual case safety report (ICSR) database (VigiBase). The review covered the period 2009-2013

Full Text available with Trip Pro

2017 Drugs - real world outcomes

15. Ivermectin treatment in humans for reducing malaria transmission [Cochrane protocol]

Ivermectin treatment in humans for reducing malaria transmission [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

16. Pharmacokinetics-Pharmacodynamics of High-Dose Ivermectin with Dihydroartemisinin-Piperaquine on Mosquitocidal Activity and QT-Prolongation (IVERMAL). (PubMed)

Pharmacokinetics-Pharmacodynamics of High-Dose Ivermectin with Dihydroartemisinin-Piperaquine on Mosquitocidal Activity and QT-Prolongation (IVERMAL). High-dose ivermectin, co-administered for 3 days with dihydroartemisinin-piperaquine (DP), killed mosquitoes feeding on individuals for at least 28 days posttreatment in a recent trial (IVERMAL), whereas 7 days was predicted pretrial. The current study assessed the relationship between ivermectin blood concentrations and the observed (...) mosquitocidal effects against Anopheles gambiae s.s. Three days of ivermectin 0, 300, or 600 mcg/kg/day plus DP was randomly assigned to 141 adults with uncomplicated malaria in Kenya. During 28 days of follow-up, 1,393 venous and 335 paired capillary plasma samples, 850 mosquito-cluster mortality rates, and 524 QTcF-intervals were collected. Using pharmacokinetic/pharmacodynamic (PK/PD) modeling, we show a consistent correlation between predicted ivermectin concentrations and observed mosquitocidal-effects

Full Text available with Trip Pro

2019 Clinical pharmacology and therapeutics

17. Dominance of P-glycoprotein 12 in phenotypic resistance conversion against ivermectin in Caenorhabditis elegans. (PubMed)

Dominance of P-glycoprotein 12 in phenotypic resistance conversion against ivermectin in Caenorhabditis elegans. While diseases caused by nematodes remains a considerable drawback for the livestock, agriculture and public health, anthelmintics drug resistance has been observed over the past years and is a major concern for parasite control. Ivermectin, initially considered as a highly potent drug, currently presents a reduced anti-helminthic efficacy, which is influenced by expression (...) of several ATP-binding cassette transporters (ABC), among them the P-glycoproteins (Pgps). Here we present some evidences of Pgps dominance during Ivermectin resistance/susceptibility using Pgps double silencing in C. elegans and the phylogenetic relationship of Pgps among nematodes, which strengthen the use of this model for study of drug resistance in nematodes. Firstly, we evaluated the quantitative gene expression of 12 out the 15 known Pgps from resistant and WT strains of C. elegans, we

Full Text available with Trip Pro

2018 PLoS ONE

18. Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. (PubMed)

Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. Yearly, millions of children are treated globally with ivermectin mainly for neglected tropical diseases. Anatomical, physiological and biochemical differences between children and adults may result in changes in pharmacokinetics. However, paediatric pharmacokinetic data of ivermectin are lacking.In the framework of a randomized controlled dose-finding trial in rural Côte d'Ivoire (...) , Trichuris trichiura-infected pre-school-aged children (PSAC, 2-5 years) and school-aged children (SAC, 6-12 years) were assigned to 100 or 200 μg/kg and 200, 400 or 600 μg/kg ivermectin, respectively (ISRCTN registry no. ISRCTN15871729). Capillary blood was collected on dried blood spot cards until 72 h post-treatment. Ivermectin was quantified by LC-MS/MS, and pharmacokinetic parameters were evaluated by non-compartmental analysis.C max and AUC increased in PSAC and SAC with ascending doses and were

Full Text available with Trip Pro

2019 Journal of Antimicrobial Chemotherapy

19. Clinical and erythema-Directed imaging evaluation of Papulo-Pustular rosacea with topical ivermectin: A 32 weeks duration study. (PubMed)

Clinical and erythema-Directed imaging evaluation of Papulo-Pustular rosacea with topical ivermectin: A 32 weeks duration study. Ivermectin (IVM) 1% cream represents an emerging therapy for papulo-pustular rosacea (PPR) and erythema-directed photography is a useful tool for evaluation of patient's erythema.The aim of our study was to assess the efficacy of IVM in PPR in achieving clear status at 8 weeks or at 20 weeks followed by respectively 24 and 12 weeks follow-up, using clinical

2019 Journal of Dermatological Treatment

20. Evaluation of Ivermectin vs Permethrin for Treating Scabies-Summary of a Cochrane Review. (PubMed)

Evaluation of Ivermectin vs Permethrin for Treating Scabies-Summary of a Cochrane Review. Is the use of ivermectin in patients infested with scabies associated with improved clinical and safety outcomes compared with permethrin?Both ivermectin and permethrin treatment were associated with high clearance rates. There is low-certainty evidence that ivermectin was associated with slightly lower rates of complete clearance after 1 week compared with permethrin, 5%, cream (relative risk [RR], 0.65

2019 JAMA dermatology (Chicago, Ill.)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>